Scandinavian ChemoTech AB Series B (CMOTEC-B) - Total Liabilities

Latest as of March 2026: Skr9.47 Million SEK ≈ $1.02 Million USD

Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has total liabilities worth Skr9.47 Million SEK (≈ $1.02 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Scandinavian ChemoTech AB Series B to track the company's year-over-year net asset growth rate.

Scandinavian ChemoTech AB Series B - Total Liabilities Trend (2014–2025)

This chart illustrates how Scandinavian ChemoTech AB Series B's total liabilities have evolved over time, based on quarterly financial data. See Scandinavian ChemoTech AB Series B free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Scandinavian ChemoTech AB Series B Competitors by Total Liabilities

The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their total liabilities.

Company	Country	Total Liabilities
Xref Ltd AU:XF1	Australia	AU$20.19 Million
Duketon Mining Ltd AU:DKM	Australia	AU$349.57K
Nictus JSE:NCS	South Africa	ZAC869.52 Million
Aston Bay Holdings Ltd V:BAY	Canada	CA$205.96K
Nyrstar NV BR:NYR	Belgium	€20.26 Million
Brunner Investment Trust LSE:BUT	UK	GBX25.11 Million
Turnstone Biologics Corp. Common Stock NASDAQ:TSBX	USA	$6.34 Million
Langgeng Makmur Industri Tbk JK:LMPI	Indonesia	Rp578.46 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Scandinavian ChemoTech AB Series B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Scandinavian ChemoTech AB Series B market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.79	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	5.78	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.85	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Scandinavian ChemoTech AB Series B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Scandinavian ChemoTech AB Series B (2014–2025)

The table below shows the annual total liabilities of Scandinavian ChemoTech AB Series B from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr10.01 Million ≈ $1.08 Million	+35.32%
2024-12-31	Skr7.40 Million ≈ $796.36K	+92.81%
2023-12-31	Skr3.84 Million ≈ $413.03K	-50.21%
2022-12-31	Skr7.71 Million ≈ $829.61K	+307.24%
2021-12-31	Skr1.89 Million ≈ $203.72K	-71.98%
2020-12-31	Skr6.75 Million ≈ $726.95K	-12.95%
2019-12-31	Skr7.76 Million ≈ $835.10K	+235.50%
2018-12-31	Skr2.31 Million ≈ $248.92K	-9.52%
2017-12-31	Skr2.56 Million ≈ $275.11K	+13.94%
2016-12-31	Skr2.24 Million ≈ $241.46K	-61.21%
2015-12-31	Skr5.78 Million ≈ $622.47K	+29367.34%
2014-12-31	Skr19.63K ≈ $2.11K	--

About Scandinavian ChemoTech AB Series B

ST:CMOTEC-B Sweden Biotechnology

Market Cap

$8.22 Million

Skr76.41 Million SEK

Market Cap Rank

#27528 Global

#603 in Sweden

Share Price

Skr3.21

Change (1 day)

+1.58%

52-Week Range

Skr2.75 - Skr7.30

All Time High

Skr51358.02